Business
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update.
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it will delay the announcement of its financial results for its fourth quarter and full-year ended December 31, 2025, and provided a corporate update.","length":534,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TDyYNi5HXQc0YIMWA0R4MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMQ--/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Company requires additional time to complete its financial reporting and anticipates filing its Annual Report on Form 10-K on or before March 31, 2026, the due date.","length":169,"tagName":"p"},{"type":"text","content":"Armata also made the following announcement related to recent developments with its business.","length":93,"tagName":"p"},{"type":"text","content":"Recent Developments: ","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced that the U.S. Food and Drug Administration (the "FDA") has granted AP-SA02, the Company's Staphylococcus aureus ("S. aureus") multi-phage product candidate, for intravenous use as a Qualified Infectious Disease Product ("QIDP") for adjunct treatment of complicated S. aureus bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin resistant S. aureus ("MRSA").","length":463,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"To achieve QIDP designation, a drug candid...